XZYFD ameliorates androgenetic alopecia through simultaneous modulation of androgen metabolism, MAPK signaling, and SREBP-1-mediated lipid metabolism, with potential advantages for patients with metabolic dysfunction. This evidence concerns the gene SREBF1 and androgenetic alopecia.